First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir I. Šikić(Stanford Medicine), Sukhmani K. Padda(Stanford University), Muralidhar Beeram(Urology San Antonio), Jie Liu(Menlo School), Kyriakos P. Papadopoulos(Texas Oncology), Sujata Narayanan(Stanford University), Mark D. Pegram(Stanford University), Matthew Axt(Menlo School), Heather A. Wakelee(Palo Alto Institute), George A. Fisher(Stanford University), Dana Supan(Stanford University), Balaji Agoram(Menlo School), Chris H. Takimoto(Menlo School), Víctor M. Villalobos(University of Colorado Cancer Center), Rhonda Aoki(Stanford University), James Y. Chen(Menlo School), A. Dimitrios Colevas(Cancer Institute (WIA)), Amita Patnaik(South Texas Accelerated Research Therapeutics), Drew Rasco(Texas Oncology), Ravindra Majeti(Stanford University), Susan Prohaska(Stanford University), Irving L. Weissman(California Institute for Regenerative Medicine), Sumit Shah(Palo Alto University), Mark P. Chao(Stanford Medicine), Jie Huang(Menlo School), Timothy J. O’Rourke(South Texas Accelerated Research Therapeutics), Sreenivasa R Chandana(South Texas Accelerated Research Therapeutics), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Maureen Howard(Stanford University), Jens-Peter Volkmer(Menlo School)
Cited by 590
Related Papers
Stem cells, cancer, and cancer stem cells
|Nature|2001|9.7k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Epigenetic memory in induced pluripotent stem cells
|Nature|2010|2.3k